3AT2 Antibody
Description
Absence in Antibody Nomenclature Databases
The Antibody Society's therapeutic antibody database ([Source 4]) lists over 200 approved or investigational antibodies, including recent entries like Divozilimab (anti-CD20) and Retifanlimab (anti-PD-1). None match the "3AT2" designation. Standard antibody naming conventions (e.g., "-mab" suffix, target-specific prefixes) further indicate "3AT2" does not align with established nomenclature.
Lack of Research Publications
A review of PubMed, Nature, and PMC archives ([Sources 1–3, 5–8]) reveals no studies referencing "3AT2 Antibody." Key topics in the provided literature include:
-
Tau-targeting antibodies (e.g., 2D6-2C6 [Source 2])
-
Aβ-targeting bispecific antibodies (e.g., RmAb158-scFv8D3 [Source 3])
-
Antibody-drug conjugates (e.g., Sacituzumab govitecan [Source 5])
Nomenclature Errors
-
"3AT2" may represent an internal lab code, non-standard abbreviation, or typographical error (e.g., confusion with 2D6-2C6, a tau oligomer-targeting antibody [Source 2]).
-
Analogous naming patterns exist (e.g., AT8, a phospho-tau antibody [Source 2]).
Proprietary or Preclinical Candidate
-
The term could denote an undisclosed therapeutic in early development, though no regulatory filings or trial registrations support this hypothesis.
Recommendations for Further Inquiry
| Action | Purpose |
|---|---|
| Verify nomenclature | Confirm spelling, target antigen, and format (e.g., monoclonal, bispecific) |
| Search proprietary databases | Explore Cortellis, Pharmaprojects, or clinicaltrials.gov |
| Contact developers | Reach out to academic labs or biotech firms specializing in novel antibodies |
Product Specs
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
STRING: 3702.AT1G03495.1
Q&A
Basic Research Questions
-
How should researchers validate the specificity of 3AT2 antibodies in immunoassays?
Validation requires a multi-step approach:-
Perform Western blotting with knockout (KO) cell lines or tissues to confirm target binding absence in negative controls .
-
Use immunoprecipitation-mass spectrometry to identify off-target interactions .
-
Validate in multiple assay formats (e.g., ELISA, immunohistochemistry) to assess context-dependent performance .
Validation Step Key Method Purpose 1 KO Validation Western blot Confirm target specificity 2 Cross-reactivity Screening Protein microarray Identify off-target binding 3 Functional Assay Correlation Neutralization/inhibition assays Link binding to biological activity -
-
What experimental design considerations are critical for 3AT2 antibody titration?
Titration should account for:-
Antigen abundance: Dilutions must reflect target concentration (e.g., 1:50–1:500 for low-abundance targets) .
-
Matrix effects: Test antibodies in biologically relevant buffers (e.g., serum-supplemented media) .
-
Batch variability: Include reference standards across experiments, especially for polyclonal preparations .
-
Advanced Research Questions
-
How can researchers resolve contradictions between in silico epitope predictions and functional data for 3AT2 antibodies?
Discrepancies often arise from:-
Conformational epitopes: AI tools like MabTope may miss structural dependencies .
-
Post-translational modifications: Glycosylation or phosphorylation near the epitope can alter binding .
Methodological approach:
-
-
What strategies improve reproducibility of 3AT2 antibody-based assays in genetic variant studies?
-
How should acidic/basic species in 3AT2 antibody formulations be analyzed?
Use orthogonal methods:
Methodological Best Practices
-
For structural studies, integrate AI-based epitope prediction with experimental validation (e.g., cryo-EM) to avoid overreliance on computational models .
-
In high-throughput screens, employ NGS-based clustering to prioritize antibodies with diverse CDR3 regions and germline origins .
-
Address batch variability in polyclonal antibodies by transitioning to recombinant monoclonals with defined sequences .
